Form 4: SR One Capital Boosts Zenas BioPharma Stake

SR One Capital Management and Simeon George increased their beneficial ownership in Zenas BioPharma, Inc. by purchasing common stock at $19 per share.

Summary

• SR One Capital Management, LLC and Simeon George, both Directors and 10% Owners of Zenas BioPharma, Inc. (ZBIO), reported acquiring additional common stock.
• On October 9, 2025, SR One Capital Management, LLC acquired 63,158 shares of common stock at a price of $19 per share.
• On the same date, an additional 63,157 shares of common stock were acquired at $19 per share.
• These acquisitions were made from the Issuer pursuant to a Securities Purchase Agreement dated October 7, 2025.
• Following these transactions, SR One Capital Opportunities Fund I, LP indirectly holds 1,173,395 shares.
• AMZL, LP indirectly holds 1,917,895 shares.
• SR One Capital Fund II Aggregator, LP indirectly holds 1,946,564 shares.
• Simeon George, M.D. is the managing member of SR One Capital Management, LLC and may be deemed to have shared power to vote or dispose of these shares, disclaiming beneficial ownership except to the extent of any pecuniary interest.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to significant insider buying by a major shareholder and director, signaling strong confidence in the company's valuation and future prospects.

Positives

• Significant insider buying by a 10% owner and director, SR One Capital Management, LLC, and Simeon George, signals strong confidence in Zenas BioPharma's future prospects.
• The purchase of 126,315 shares at $19 per share represents a substantial investment by key stakeholders.
• The transaction was executed through a Securities Purchase Agreement, indicating a structured and deliberate investment.

Future Outlook

The filing does not provide explicit forward-looking statements or guidance from the company, but the insider purchase may implicitly signal a positive outlook from the reporting persons.

Management Comments

• Simeon George, M.D. is the managing member of SR One Capital Management, LLC. Each of SR One Capital Opportunities Partners I, LP, SR One Capital Management, LLC and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.

Industry Context

Insider buying, particularly by significant shareholders and directors in the biotechnology sector, is often interpreted by the market as a strong vote of confidence in the company's pipeline, strategic direction, or upcoming catalysts. This transaction aligns with a trend where institutional investors and management increase stakes when they perceive undervaluation or significant growth potential.

Comparison to Industry Standards

• Insider purchases are generally viewed positively across industries, signaling management's belief in the company's prospects. For example, similar insider buying patterns have been observed in other biotech firms like Moderna (MRNA) or BioNTech (BNTX) during key development phases or after significant clinical trial results, often preceding periods of stock appreciation.
• The acquisition price of $19 per share provides a benchmark for the reporting persons' valuation of Zenas BioPharma's common stock at the time of the transaction, which can be compared to the prevailing market price to gauge their conviction.

Related Party Transactions

• The transactions involve SR One Capital Management, LLC and Simeon George, both identified as 10% owners and directors of Zenas BioPharma, Inc., making these related party transactions.

Stakeholder Impact

• Shareholders: May view this insider buying as a strong positive signal, potentially increasing investor confidence and demand for the stock.
• Company (Zenas BioPharma): Benefits from the capital raised through the issuance of shares, which can be used for operations, research, or development.

Key Dates

Recommendation

The substantial insider purchase by a 10% owner and director at a fixed price of $19 per share indicates strong conviction in Zenas BioPharma's current valuation and future potential. Such a significant vote of confidence from key stakeholders often precedes positive developments or reflects an belief that the stock is undervalued, making it a compelling 'buy' signal for seasoned investors.

Keywords

Zenas BioPharma, ZBIO, SR One Capital Management, Simeon George, Insider Buying, Form 4, Equity Purchase, Biopharma Investment, 10% Owner, Director